2 completed, 2 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 2 |
Follow CinDome Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg - Idiopathic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 416 | 2025-01-29 | 2026-07-13 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis CIN-102 Dose 15mg or 10mg, Placebo - Diabetic Gastroparesis | Phase 2 | Completed | CinDome Pharma, Inc. | 382 | 2023-03-27 | 2025-12-17 |
| A Scintigraphy Study in Adults With Diabetic Gastroparesis CIN-102 Dose 1, CIN-102 Dose 2, Placebo for CIN-102 - Diabetic Gastroparesis | Phase 2 | Terminated | CinDome Pharma, Inc. | 2 | 2020-02-17 | 2021-08-10 |
| A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3 - Gastroparesis | Phase 2 | Terminated | CinDome Pharma, Inc. | 72 | 2019-09-11 | 2026-03-25 |
Gastroparesis (3) · Nausea (2) · Vomiting (2) · Abdominal Pain (1) · Digestive System Diseases (1) · Gastrointestinal Diseases (1)
CIN-102 (1)
United States (4)